Nkarta, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Nkarta (NKTX, ~$82.6M market cap) reported Q2 2026 financials with cash/equivalents/investments of $243.2M as of June 30, 2026, expected to fund operations into 2029. The company continued enrollment in Ntrust-1 and Ntrust-2 trials at 4 billion cells per dose (12 billion total in 3-dose cycle) with outpatient dosing now underway at community sites following FDA agreement. Q2 net loss was $40.4M ($0.54/share); R&D expenses $29.0M, G&A $14.1M. Initial clinical data from both trials planned for presentation at a medical conference in 2026.
Why this rating
Clinical progress is encouraging, but cash burn ($68.2M in H1 2026) consumes ~28% of market cap annually. Runway into 2029 is adequate but not generous for early-stage biotech. Event is ordinary disclosure with no major deal, restatement, or inflection point.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.